CSF Alzheimer's disease-like pattern in Corticobasal Syndrome: evidence for a distinct disorder. by Borroni B. et al.
CSF Alzheimer’s disease-like pattern in corticobasal
syndrome: evidence for a distinct disorder
Barbara Borroni,1 Enrico Premi,1 Chiara Agosti,1 Antonella Alberici,1 Carlo Cerini,1
Silvana Archetti,2 Alessia Lanari,3 Barbara Paghera,4 Silvia Lucchini,4 Luigi Caimi,2
Alessandro Padovani1
ABSTRACT
Background Corticobasal syndrome (CBS) has
a heterogeneous neuropathological spectrum, ranging
from the classical corticobasal degeneration to
Alzheimer’s disease (AD). The neuropathology of CBS is
still unpredictable. CSF tau/abeta ratio is a reliable
marker of AD.
Objective To evaluate the presence of a distinct clinical
and neuroimaging CBS phenotype according to CSF
pattern.
Methods 30 patients fulfilling current clinical criteria for
CBS entered the study. Each patient underwent a clinical
and standardised neuropsychological assessment, and
CSF analysis (total tau and abeta42 dosages). CSF AD-like
pattern and CSF non-AD like pattern (nAD-like) were
identified. In 23 CBS cases, 99mTc-ECD single photon
emission computed tomography (SPECT) scan was
performed and analysed by statistical parametric mapping.
Results CSF AD-like pattern was reported in six cases
(20%). The two subgroups did not differ in demographic
characteristics or global cognitive impairment. The AD-like
group showed greater impairment of memory
performances, language and psychomotor speed while the
nAD-like group had more severe extrapyramidal syndrome
with comparable apraxia scores. Voxel by voxel analysis
on SPECT images demonstrated that CBS AD-like patients
had greater hypoperfusion in the brain areas typically
affected by ADdnamely, precuneus, posterior cingulate
and hippocampus, bilaterallydcompared with nAD-like
patients (p<0.001). No clusters above the pre-established
threshold were detected when nAD-like were compared
with AD-like patients.
Conclusions CSF AD-like profile in CBS is associated with
earlier memory impairment and brain abnormalities
typically found in classical AD. These findings argue for the
usefulness of CSF testing to identify AD in CBS, and might
suggest a different pharmacological approach on the basis
of biological data.
INTRODUCTION
Current clinical criteria for corticobasal syndrome
(CBS) describe this disorder as an asymmetric,
akinetic rigid syndrome, levodopa resistant, associ-
ated with prominent apraxia, cortical sensory loss,
focal reﬂex myoclonus, dystonia, alien limb
phenomena and without early dementia.1e3
As originally conceived, the neuropathology of the
disease was considered as a speciﬁc disorder, namely
corticobasal degeneration (CBD), characterised by
cortical degeneration with swollen ‘achromatic’
neurons, neuronal loss in the substantia nigra and
extensive neuronal and glial cytoplasmic tau positive
inclusions.1 However, more recently, there is
growing evidence that patientswith clinically classic
CBS have alternative pathologies.4 It has been
reported that CBS is frequently associated with
Alzheimer ’s disease (AD) pathology which is
present in 15e20% of cases.5e8 Notwithstanding,
the neuropathological features of CBS are still
unpredictable in life.
Two retrospective studies tried to identify
predictors in vivo of the speciﬁc neuropathology by
comparing the clinical features of patients
presenting with CBS who had either pathological
changes of CBD or AD at post mortem. The ﬁrst
study suggested that early episodic memory
impairment versus early behavioural symptom-
atology appears to best differentiate AD from
CBD,9 while the other did not report any neuro-
psychological difference in the different neuro-
pathological subtypes.10
Detecting AD in CBS has several clinical impli-
cations and might be associated with a different
disease course and speciﬁc therapeutic approaches.
It has been widely demonstrated that AD is
characterised by a signiﬁcant decrease in the CSF
tau/abeta42 ratio, which allows AD to be distin-
guished from other neurodegenerative disorders.11 12
The high sensitivity and speciﬁcity of the
biomarker strongly suggests the introduction of the
CSF tau/abeta42 ratio into current clinical criteria
to further support the diagnosis, even at the
preclinical disease stages.13 As the biological marker
mirrors the pathogenetic mechanisms of AD, it can
be hypothesised that the CSF tau/abeta42 ratio
might identify AD not only in the presymptomatic
phase but also in the atypical presentation of the
disorder.
These observations deﬁned the aims of the
present work. We sought to: (1) evaluate the pres-
ence and percentage of CSF AD-like patterndthat
is, high CSF tau/abeta ratiodin a consecutive
sample of CBS patients who underwent lumbar
puncture; (2) assess the neuropsychological proﬁle
in AD-like CBS patients, thus fulﬁlling current
clinical criteria of CBS but with CSF AD-like
abnormalities, and in non-AD like (nAD-like) CBS;
and (3) evaluate the cerebral blood perfusion
correlates at neuroimaging in the two groups.
METHODS
Subjects
Thirty CBS patients (21 men and nine women;
mean age6SD 63.568.9 years) recruited from the
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Centre for Neurodegenerative Diseases and the Centre for
Movement Disorders, University of Brescia, Italy, entered the
study.
All subjects underwent a somatic and neurological evaluation,
and routine laboratory examination, and received a brain structural
study.
The following essential diagnostic core criteria were fulﬁlled
by all subjects: (a) insidious onset and gradual progression, (b)
asymmetrical presentation, (c) akinetic rigid syndrome, (d)
apraxia, as measured by de Renzi apraxia test,14 and (e) lack of
sustained response to levodopa therapy. The supportive criteria
included: (a) myoclonus, (b) limb dystonia, (c) cortical sensory
loss and (d) alien limb phenomena. In each patient, the extra-
pyramidal syndrome developed ﬁrst and was followed by
cognitive changes.
Moreover, all CBS patients had been followed for at least
1 year after entering the study and the diagnosis of CBS was
conﬁrmed in all cases at the follow-up evaluation by clinical and
neurological re-examination.
Stringent exclusion criteria were applied, as follows: (a) early
dementia, early vertical gaze palsy, rest tremor, severe autonomic
disturbances, sustained responsiveness to levodopa; (b) cerebro-
vascular disorders, hydrocephalus and intracranial mass, docu-
mented by MRI; (c) a history of traumatic brain injury or another
neurological disease; and (d) signiﬁcant medical problems.
All participants were right handed and were made fully aware
of the aims of the research. Informed consent was sought from
all subjects. The study was conducted in accordance with local
clinical research regulations and conformed to the Helsinki
Declaration.
Clinical and neuropsychological assessment
Motor impairment was evaluated by the motor section of the
Uniﬁed Parkinson’s Disease Rating Scale (UPDRS-III).15 Instru-
mental Activities of Daily Living and Basic Activities of Daily
Living were also assessed. Behavioural and psychiatric distur-
bances were evaluated by the Neuropsychiatry Inventory16 and
Frontal Behavioural Inventory.17 Apraxia was assessed by the De
Renzi test14 and both arms were examined separately.
Assessment of global cognitive functions was carried out
according to a standardised battery, blind to clinical diagnosis (as
reported in table 1).
CSF analyses
Lumbar puncture was performed on an empty stomach
according to a standardised protocol, in the outpatient clinic,
from 09:30 to 10:30, after informed written consent had been
obtained. CSF was collected in sterile polypropylene tubes and
gently mixed to avoid gradient effects. Routine chemical
measures were determined. The remaining CSF was centrifuged
for 3 min at 3000 rpm, and aliquots were stored at 808C or in
liquid nitrogen for subsequent total tau, phospho-tau and and
abeta dosages. CSF concentrations were measured in duplicate
by an ELISA test (Innotest hTau antigen kit and Innotest
PHOSHO-TAU 181P; Innogenetics, Ghent, Belgium). Interassay
variability was less than 7%. According to our laboratory stan-
dards, the cut-off value for total tau is <400 pg/ml and for abeta
>400 pg/ml. The AD pattern is deﬁned by high total tau levels
and low abeta42 levels in CSF and, as previously reported by
other authors, with a CSF tau/abeta42 ratio >1.18
99mTc-ECD SPECT acquisition and imaging processing
For brain functional data comparisons, a group of 14 age
matched healthy subjects were recruited among patients’
spouses or relatives and were included as normal controls. They
were interviewed, assessed for neurological or cognitive
dysfunction, evaluated for diseases that were exclusion criteria
for the patient group, and underwent a brain single photon
emission computed tomography (SPECT) study.
Both patients and controls were administered an intravenous
injection of 1110 MBq 99mTc-ECD (ethylcysteinate dimer,
Neurolite; Bristol-Myers Squibb Pharma, New York, USA) under
resting conditions, lying supine in a quiet, dimly lit room. All
subjects were imaged using a dual head rotating g camera (VG
Millenium GE) ﬁtted with a low energy, high resolution colli-
mator, 30 min after intravenous injection of 99mTc-ECD.
A 1283128 pixel matrix was used for image acquisition with
120 views over a 3608 orbit (in 38 step) with a pixel size and slice
Table 1 Neuropsychological, behavioural and motor assessment according to CSF pattern
Variable CBS (n[30)
CBS CBS with SPECT study available
nAD-like (n[24) AD-like (n[6) p Value nAD-like (n[18) AD-like (n[5) p Value
MMSE 23.666.1 (36.6) 24.066.2 (29.2) 21.365.8 (66.6) 0.324 25.163.6 (27.7) 23.064.6 (60%) 0.289
Short Story 6.964.3 (66.6) 7.864.3 (58.3) 3.562.4 (100) 0.014 8.064.0 (55.5) 3.862.6 (100) 0.040
Raven C Matrices 17.268.0 (43.3) 18.367.6 (41.6) 12.568.5 (50.0) 0.109 18.566.3 (38.8) 15.066.5 (40.0) 0.284
Rey Figure, copy 18.5611.8 (72.4) 20.5611.2 (69.5) 10.9612.3 (83.3) 0.078 21.069.4 (72.2) 12.8612.7 (80.0) 0.126
Rey Figure, recall 6.765.7 (65.5) 7.165.6 (65.2) 4.966.3 (66.6) 0.403 7.165.0 (66.6) 5.966.5 (60.0) 0.644
Phonological fluency 16.7610.0 (50.0) 16.6610.3 (50.0) 17.1610.0 (50.0) 0.916 16.368.3 (50.0) 20.267.6 (40.0) 0.369
Semantic fluency 26.5610.5 (50.0) 27.1610.5 (45.8) 24611.4 (66.6) 0.527 26.768.4 (50.0) 26.6610.6 (60.0) 0.979
Digit Span 4.661.5 (13.3) 4.661.6 (12.5) 4.661.0 (16.6) 0.953 4.760.9 (5.5) 4.661.1 (20.0) 0.801
Token Test 27.267.6 (37.0) 28.467.5 (26.0) 20.363.5 (100) 0.048 29.864.1 (17.6) 21.563.2 (100) 0.004
Trail Making A 168.96153.8 (59.2) 123.66103.7 (47.6) 327.56202.9 (83.3) 0.002 103.5656.5 (50.0) 2936206.3 (80.0) 0.003
Trail Making B 339.96167.8 (60.0) 325.456161.2 (40.0) 398.06139.7 (60.0) 0.367 329.46160.4 (60.0) 372.56147.3 (50.0) 0.634
NPI 10.4610.7 9.9610.3 12.6613.0 0.584 8.268.6 8.468.6 0.968
FBI, A 6.867.0 6.266.8 8.868.3 0.446 5.465.8 5.864.3 0.886
FBI, B 1.362.3 1.162.2 1.862.7 0.522 0.761.0 0.861.3 0.892
FBI, AB 8.068.5 7.467.9 10.6610.9 0.419 6.166.2 6.664.9 0.873
UPDRS-III 19.9611.5 22.7610.7 7.264.4 0.004 21.6610.5 6.765.0 0.014
De Renzi imitation, left* 55.9614.1 (92.6) 56.5614.2 (95.4) 53.4615.2 (80.0) 0.663 59.2611.6 (94.1) 59.069.9 (75.0) 0.963
De Renzi imitation, right* 58.0610.2 (96.3) 57.0610.6 (100) 62.667.3 (80.0) 0.289 58.3610.6 (100) 63.268.3 (75.0) 0.403
Percentages of patients with pathological scores, according to Italian normative data, are indicated in parentheses.
*De Renzi cut-off value of <62 is used.
AD, Alzheimer’s disease; CBS, corticobasal syndrome; FBI, Frontal Behavioural Inventory; MMSE, Mini-Mental State Examination; nAD-like, non-Alzheimer’s disease-like; NPI, Neuropsychiatry
Inventory; SPECT, single photon emission computed tomography; UPDRS-III, Unified Parkinson’s Disease Rating Scale.
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thickness of 1 mm, in 27 min or more if total counts were lower
than 53106. Image reconstruction was performed by a ramp
ﬁltered back projection and three-dimensionally smoothed with
a Metz ﬁlter (order 3, enhancement 1.24, FWHM 6.7 mm,
cut-off 0.61 cycles/cm). The reconstructed images were
corrected for g ray attenuation using the Chang method
(attenuation coefﬁcient 0.11/cm).
Statistical Parametric Mapping (SPM2, Welcome Department
of Cognitive Neurology, University College, London, UK) and
Matlab 6.1 (Mathworks Inc, Sherborn, Massachusetts, USA)
were used for image preprocessing. Images were spatially
normalised to a reference stereotactic template (Montreal
Neurological Institute) and smoothed by a Gaussian kernel of
83838 mm FWHM. Global differences in the distribution and
the effect of age and gender on the tracer ’s uptake were cova-
riated out for all voxels. Comparisons across the different groups
were made using t statistics with appropriate linear contrasts.
We considered any cluster above a statistical threshold set at
p<0.001.
Statistical analysis
Demographic and clinical characteristics between groups were
compared by Pearson’s c2 test or the ManneWhitney test, as
appropriate. Statistical signiﬁcance was assumed at p<0.05.
RESULTS
Subject descriptions
Mean age at onset was 61.069.3 and in 60% of cases the disease
began on the left side (see table 2 for demographic characteristics).
In the overall group, mean CSF abeta levels were within the
normal range whereas CSF tau levels were slightly increased. As
reported in the method section and in ﬁgure 1, according to the
CSF pattern, CBS patients were subdivided into AD-like (n¼6,
20%) and nAD-like (n¼24, 80%) groups. CSF tau and abeta
levels as well as CSF tau/abeta ratio are reported in table 2.
Neuropsychological, behavioural and motor assessment
The neuropsychological, behavioural and motor assessment of
CBS patients is presented in table 1. Mean Mini-Mental State
Examination score was within the normal range. Behavioural
disturbances were present in some CBS patients and the most
common disorder was apathy.
AD-like and nAD-like CBS did not differ in terms of global
cognitive impairment but the former performed signiﬁcantly
worse in tests assessing episodic memory (Short Story), language
comprehension (Token Test) and psychomotor speed (Trail
Making A). The performances tapping the other cognitive
domains, including praxis (De Renzi test), were comparable, as
well as the degree of behavioural disturbances as measured by
the Frontal Behavioural Inventory. Conversely, nAD-like CBS
showed a more severe extrapyramidal syndrome, as measured by
UPDRS-III, compared with AD-like CBS.
Imaging analysis
Twenty-three out of 30 CBS patients (ﬁve AD-like and 18
nAD-like) underwent a SPECT scan (see table 1 for neuro-
psychological assessment), and hypoperfusion patterns in
AD-like versus nAD-like cases were evaluated. Overall, CBS
patients showed signiﬁcantly greater hypoperfusion in the
superior (48,46, 2, T¼3.29) and middle temporal (38, 62,
18, T¼2.87) gyri and in the inferior parietal lobule (50, 28,
28, T¼3.25) compared with age matched controls (p<0.001).
Accordingly, when the two subgroups of CBS patients (AD-like
and nAD-like) were compared with controls, the same pattern
of hypoperfusion was observed (AD-like versus controls: 50,
44, 2, T¼4.72; 54, 32, 28, T¼3.35; and nAD-like versus
controls: 40, 56, 14, T¼2.94).
As reported in table 3 and ﬁgure 2, in AD-like CBS, greater
hypoperfusion of the hippocampus and parahyppocampal gyrus,
posterior cingulate and precuneus, bilaterally, was demonstrated
(AD<nAD, p<0.001) than in nAD-like CBS. Conversely, no
voxels above the pre-established threshold were identiﬁed
when nAD-like patients were compared with AD-like patients
(nAD<AD).
DISCUSSION
In the present work, we reported that patients with classic CBS
have two distinct proﬁles of CSF tau/abeta ratio, 20% presenting
with an AD-like pattern. No differences in demographic
Figure 1 CSF tau/abeta ratio in Alzheimer’s disease (AD)-like and non-
AD-like groups.
Table 2 Demographic and clinical characteristics according to CSF pattern
Variables CBS (n[30)
CBS CBS with SPECT study available
nAD-like (n[24) AD-like (n[6) p Value nAD-like (n[18) AD-like (n[5) p Value
Age at evaluation (years) 63.568.9 63.669.8 63.064.0 0.882 62.2610.4 63.664.2 0.779
Gender (F%) 30.0 33.3 16.7 0.426 38.9 0 0.095
Age at onset (years) 61.069.3 60.9610.3 61.664.3 0.865 60.6611.0 62.264.6 0.768
Education (years) 6.662.9 6.9563.2 5.360.8 0.238 7.263.2 5.460.9 0.235
Family history (%) 13.3 12.5 16.7 0.788 5.6 20.0 0.311
Side at onset (left%) 60.0 54.2 83.3 0.417 50.0 80.0 0.231
APO E (34%) 23.3 20.8 33.3 0.517 27.8 40.0 0.599
CSF markers
CSF abeta (pg/ml) 748.26431.5 865.26402.5 280.2677.3 0.002 889.96412.5 266.1677.2 0.003
CST tau (pg/ml) 409.16285.3 337.76242.5 694.76281.7 0.004 308.16223.1 726.56302.7 0.002
CSF tau/abeta ratio 0.8661.03 0.4360.29 2.6061.20 <0.001 0.4460.46 2.8361.10 <0.001
AD, Alzheimer’s disease; CBS, corticobasal syndrome; nAD-like, non-Alzheimer’s disease-like; SPECT, single photon emission computed tomography.
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characteristics were detected between groups, and apraxia scores
were comparable. Compared with nAD-like CBS, AD-like
patients reported earlier memory impairment as well as worse
psychomotor speed and language dysfunctions. Conversely,
nAD-like patients had a more severe akinetic extrapyramidal
syndrome. Finally, in AD-like CBS patients, CSF and neuro-
psychological proﬁles were corroborated by greater hypo-
perfusion in those areas typically affected by ADdnamely, the
hippocampus, parahyppocampal region, precuneus and posterior
cingulate, bilaterally.
A few studies on CSF markers in CBS are already available,
reporting conﬂicting results. In two studies, CSF tau protein
dosage was signiﬁcantly higher in CBS than in healthy
controls19 20 whereas three other studies showed no signiﬁcant
differences between CBS and patients affected by neurodegen-
erative diseases with distinct tau related pathology.21e23
However, despite the conﬂicting results and lack of compar-
ison groups, all of the above studies reported high variability in
CSF markers, arguing for different associated neuropathological
features.
In clinically deﬁned CBS, CSF ﬁndings are still unpredictable
but it is widely demonstrated that AD is associated with
a speciﬁc pattern of CSF abnormalitiesdthat is, high tau and
low abeta levels compared with other neurodegenerative
Figure 2 Reduction of regional
cerebral blood flow in corticobasal
syndrome (CBS) with CSF Alzheimer’s
disease (AD)-like pattern compared
with CSF non-AD-like pattern. Greater
hypoperfusion in the hyppocampi (top
row) and posterior cingulate (bottom
row) in AD-like versus non-AD-like CBS
patients is reported. L, left; R, right.
Table 3 Location of the peaks of reduction of regional cerebral blood flow in corticobasal syndrome with
CSF AD-like pattern compared with nAD-like pattern
Brain region
Peak coordinates (mm)
T p Value Cluster sizex y z
CBS-AD versus CBS-nAD (AD<nAD)
Precuneus (R) 18 52 32 5.77 <0.001 621
Posterior cingulate (R) 16 42 10 4.23 <0.001 e
Hippocampus (R) 24 16 18 5.41 <0.001 937
Parahippocampal gyrus (R) 26 2 12 3.77 <0.001 e
Precuneus (L) 18 44 46 4.79 <0.001 1390
Posterior cingulate (L) 20 70 20 4.72 <0.001 2175
Hippocampus (L) 30 40 10 4.81 <0.001 e
Parahippocampal gyrus (L) 38 42 8 4.91 <0.001 e
CBS-nAD versus CBS-AD (nAD<AD)
None e e e e e e
Corticobasal syndrome; x, y and z values localise the areas of regional cerebral blood flow reduction according to the Montreal
Neurological Institute stereotactic coordinates.
AD, Alzheimer’s disease; CBS, corticobasal syndrome; L, left; nAD, non-Alzheimer’s disease-like; R, right.
J Neurol Neurosurg Psychiatry 2011;82:834e838. doi:10.1136/jnnp.2010.221853 837
Research paper
 group.bmj.com on October 22, 2012 - Published by jnnp.bmj.comDownloaded from 
disorders.11 To date, the CSF tau/abeta marker has been strongly
suggested as a supportive criterion for early and preclinical AD
diagnosis.13
Herein, we have tested the hypothesis that different CSF
patternsdthat is, AD-like and nAD-likedmight deﬁne distinct
CBS phenotypes. In fact, although diagnostic criteria for CBS
arose from clinical cases with pathologically conﬁrmed CBD,24
it has been shown that AD can also be a common cause of
CBS.4 8 10 25 26 This pathological heterogeneity likely reﬂects the
range of neurodegenerative disorders which can present with
asymmetric frontal and/or parietal lobar dysfunction,10 but
clinical or neuropsychological CBS features useful to distinguish
AD cases are not yet clear. One study evaluated 12 patients
with CBS who had been followed prospectively; six had AD and
six had classic CBD neuropathology. After review of the
presenting clinical features, the authors reported that the initial
episodic memory complaints and poor performance on the
combined orientationememory subtest of the Addenbrooke’s
Cognitive Examination reliably predicted AD pathology.9
We also demonstrated that patients with a CSF AD-like
pattern had greater hypoperfusion in those brain areas typically
affected by classic ADdnamely, the hippocampus, para-
hyppocampal region, precuneus and posterior cingulate. These
brain areas have been found to be affected even from the early
stages and represent the preclinical neuroimaging hallmarks of
those subjects who will develop a symptomatic dementia of the
AD type.27 Up until now, no other neurodegenerative disorder
has been characterised by these neuroimaging features, claiming
that the presence of hippocampal and posterior cingulate
hypoperfusion is suggestive of AD.27
We may alternatively hypothesise that CSF formula, along
with neuroimaging ﬁndings suggestive for AD pathology, may
herald in these CBS patients the onset of a dementia that can
develop in their later life.
We acknowledge that this work has some limits. Firstly, the
neuropathological conﬁrmation and the combined use of
amyloid b tracers would be mandatory to deﬁnitively clarify the
present ﬁndings. Secondly, a more careful evaluation of memory
deﬁcits might be of help for further differentiating AD-like and
nAD-like subgroups. Thirdly, the neuroimaging data analysis
herein was uncorrected for multiple comparisons, thus limiting
the conclusions that can be derived. These need further valida-
tion in larger and independently assessed cohorts.
Moreover, it is interesting to observe that total tau levels in
CSF were normal for the majority of our CBS cases. We can
therefore argue that the tauopathy found at neuronal and glial
cytoplasmic inclusions at autopsy is not detectable by this
ELISA, but other technologies should be developed to measure
and disentangle the molecular mechanisms of tau deposition in
CBS.
However, taken together, these data suggest that the CSF tau/
abeta ratio might be a potential avenue for detecting AD cases
presenting with CBS. In the near future, CSF data alone, or in
combination with other neuropsychological or neuroimaging
markers, might improve the accuracy of an AD-like diagnosis
and might be included in research criteria to identify a distinct
population. If conﬁrmed by future studies, patients with an
AD-like pattern should undergo a different therapeutic
approach, and current pharmacological treatment for AD should
be considered.
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